# Exhibit 6

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLORADO
JUDGE DANIEL D. DOMENICO

CIVIL ACTION NO. 1:22-cv-03181-DDD-KLM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION,

Plaintiff,

v.

REVEN HOLDINGS, INC. d/b/a Reven Pharmaceuticals;
REVEN PHARMACEUTICALS, INC.;
BRIAN D. DENOMME;
PETER B. LANGE; and
MICHAEL A. VOLK,

Defendants, and

REVEN, LLC;
REVEN IP HOLDCO, LLC;
REVEN ONCOLOGY LICENSING, LLC; and
HEALTH ANALYTICS AND RESEARCH SERVICES, LLC,

Relief Defendants.

---

DECLARATION OF HENK VAN WYK

---

I, Henk van Wyk, declare as follows:

1. My name is Henk van Wyk. I am over 18 years old, and I am competent to make this declaration. I have personal knowledge of the facts stated in this declaration. The statements in this declaration are true and correct to the best of my knowledge.

2. I am the Chief Scientist of Reven Holdings, Inc. and Reven, LLC (collectively, "Reven") and the inventor of Rejuveinix ("RJX"). My wife, Mariette van Wyk, is Head of Quality Assurance at Reven.

3. Before I was formally employed at Reven in 2014, I was head of Research and Development at Inmed (Innovative Medical Products) in Johannesburg.

4. I hold a Masters Degree in Pharmacology, and my research activities were focused on sterile injectable formulations and delivery systems. The dissertation for my PhD was submitted prior to my departure to the USA.

5. For the past 10, years I have worked closely with Reven's three founders, Peter Lange, Brian Denomme, and Michael Volk (the "Reven Founders"). Throughout this time, I have believed in the Reven Founders' ability to commercialize RJX, including by working tirelessly to bring RJX through clinical trials, and, eventually, create an exit opportunity for Reven's shareholders.

6. In approximately late May or early June 2022, I became aware through a mutual contact that Lee-ann Frost and Leah Schaatt intended to take over the management of Reven and/or its intellectual property.[1] Frost and Schaatt eventually made communications to that effect directly to my wife and I during and throughout 2022.

7. In October 2022, my wife and I participated in a Zoom call with Frost and Schaatt during which Frost and Schaatt reiterated their intent to take over Reven and its intellectual property. During this call, Frost and Schaatt requested additional information (i.e., employment contracts) about the involvement of my wife and I in the development of the Reven patents and intellectual property.

8. In approximately March of 2023, I was also contacted by Jim Ervin, Reven's former Chief Technology Advisor, about a new venture that seems related to Reven. According to Ervin,

[1] I understand that both Ms. Schaatt and Ms. Frost have provided declarations supporting the SEC's allegations in this action.

the name of this venture is "Veterinary Neutraceuticals." My understanding is that Jim Ervin had been coordinating with Frost and Schaatt for some time prior to this communication.

9. For example, on May 5, 2023, Ervin called me to try to solicit my help with Veterinary Neutraceuticals. During our conversation, Ervin specifically mentioned that Reven and the Reven Founders could be "tied up" in court for up to 2 years, or even longer. I understood that his comments referred to this litigation.

10. Ervin also directly revealed to me that Frost and Schaatt are working with him on Veterinary Neutraceuticals. For example, a slide deck that Ervin shared with me stated that Ms. Schaatt and Ms. Frost would be providing "Capital and Business Oversight" to this venture.

11. The same slide deck also named two veterinary partners, Judith Shoemaker and Jamie Minell, that Reven had formerly worked with on a pilot study in Pennsylvania. Indeed, the format and content of the slide deck appeared extremely similar to Reven slides that I have seen in the past.

12. On May 11, 2023, Ervin requested my wife and I delete data and communications relating to our prior communications from our laptops. The laptops have been provided by Reven and are used to perform work for Reven. When I expressed to him my belief that such activity would be both illegal and unethical, Ervin seemed distressed. He also seemed very upset that Mr. Lange seemed to know that Ervin was involved in setting up another business plan.

Under 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct.

Executed on: June 8, 2023

Henk van Wyk